Andre T et al. Phase II study of an optimized 5- fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study. Ann Oncol 2007;18(1):77-81.
Abstract

Blum JL et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7(11):850-6. Abstract

Burstein HJ et al. Cognitive side-effects of adjuvant treatments. Breast 2007;16(Suppl 2):166-8. Abstract

Gamelin L et al. Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008;26(7):1188-9. No abstract available

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358(23):2482-94. No abstract available

Kris MG et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24(18):2932-47.
Abstract

Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12(5):601-9. Abstract

Nakade S et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 2008;63(1):75-83. Abstract

NCCN Antiemesis Guidelines Pertaining to Nausea and Vomiting. NCCN Guidelines for Supportive Care. Available at: www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: Diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6(6):455-67. Abstract

Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR study. J Clin Oncol 2006;24(3)394- 400. Abstract